FDA inspection
Hanlim Pharm Co. Ltd.: FDA inspection ending Apr 10, 2026
FDA inspection 1316122 · No Action Indicated (NAI) · Yongin
Key facts
| Inspection ID | 1316122 |
|---|---|
| Firm | Hanlim Pharm Co. Ltd. |
| FEI number | 3004886113 |
| Address | Hallimjeyakjungangyeonguso, 2-27 Yeongmun-Ro; Cheoin |
| City | Yongin |
| Country | Korea (the Republic of) |
| Fiscal year | 2026 |
| Inspection end date | Apr 10, 2026 |
| Classification | No Action Indicated (NAI) |
| Project area | Bioresearch Monitoring |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data